immunoprophylaxis


Also found in: Encyclopedia.

immunoprophylaxis

[-prō′filak′sis]
the introduction of active immunization through vaccines or passive immunization through antisera.

immunoprophylaxis

Prevention of disease by the use of vaccines.

immunoprophylaxis (imˈ·my·nō·prōˈ·f·lakˑ·ss),

n prevention of illness by the introduction of active immunization by vaccines or passive immunization through antisera.

immunoprophylaxis

prevention of disease by the administration of vaccines or hyperimmune sera.
References in periodicals archive ?
The decrease in positive RSV infections may be due to the introduction of immunoprophylaxis to high-risk patients.
The cost implication of offering solely passive prophylaxis during intensive chemotherapy of patients with leukaemia and non-Hodgkin's lymphoma led to discontinuation of this protocol and a recommendation for simultaneous passive and active immunoprophylaxis from the start of such therapy.
Alteration of the influences of HLA classes I and II alleles on the perinatal hepatitis B virus infection after immunoprophylaxis in Korean children.
Risk of vertical transmission occurs in a large number of cases in the absence of immunoprophylaxis.
Healthcare providers and public health officials can use information on RSV circulation to guide diagnostic testing and timing of RSV immunoprophylaxis for children at high risk for severe respiratory infection.
Palivizumab immunoprophylaxis is the only available measure to prevent severe RSV disease.
Now, biologists at Caltech led by Nobel Laureate David Baltimore, president emeritus and Robert Andrews Millikan Professor of Biology, have taken one step closer to that goal and have developed a new approach to HUIV prevention, called Vectored ImmunoProphylaxis or VIP.
The failure of immunoprophylaxis might be due to factors such as lack of prevailing serotypes of FMD virus in the vaccine, inappropriate amount of immunogen/ vaccine dose, lack of cold chain, concurrent disease or prevailing biological and chemical immuno-suppressants (Meyer and Knudersen, 2001).
ATLANTA -- In the wake of a Food and Drug Administration advisory panel vote against recommending licensure of a new drug for the prevention of respiratory syncytial virus, a Centers for Disease Control and Prevention working group on RSV immunoprophylaxis will continue to develop recommendations for the use of currently available products, the group's chair said.
On the basis of these findings, the American Academy of Pediatrics Committee on Infectious Diseases and the Committee on Fetus and Newborn revised indications for use of palivizumab because the results of the 76-center study "demonstrated the safety and efficacy of monthly palivizumab immunoprophylaxis in infants and children with hemodynamically significant congenital heart disease," Dr.
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: A consensus opinion.